Vaxcyte/PCVX

$81.05

2.63%
-
1D1W1MYTD1YMAX

About Vaxcyte

Vaxcyte Inc. is a clinical-stage vaccine company. The Company develops conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its synthetic techniques include advanced chemistry and the XpressCF cell-free protein synthesis platform, licensed from Sutro Biopharma, Inc., or Sutro Biopharma. Its pipeline includes Pneumococcal conjugate vaccine (PCV), VAX-A1, VAX-PG and VAX-GI. Its lead vaccine candidate, VAX-24, is a 24-valent investigational PCV being developed for the prevention of invasive pneumococcal disease (IPD). Its second PCV candidate, VAX-31, is designed to prevent IPD. population. VAX- 24 is intended to improve upon the standard-of-care PCV vaccines for both children and adults. VAX-A1 is a conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus or Group A Strep. VAX-PG is a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis. VAX-GI is a vaccine program designed to prevent Shigella.

Ticker

PCVX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Grant Pickering

Employees

158

Headquarters

San carlos, United States

Vaxcyte Metrics

BasicAdvanced
$8.15B
Market cap
-
P/E ratio
-$3.30
EPS
0.93
Beta
-
Dividend rate

What the Analysts think about Vaxcyte

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
0.23% downside
High $108.00
Low $68.00
$81.05
Current price
$80.86
Average price target

Vaxcyte Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-92.6M
35.58%
Profit margin
0%
-

Vaxcyte Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 8.66%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$1.02
-$0.70
-$0.70
-$0.91
-
Expected
-$0.93
-$0.83
-$0.75
-$0.84
-$1.07
Surprise
9.68%
-15.22%
-6.04%
8.66%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Vaxcyte stock

Buy or sell Vaxcyte stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing